Ember Therapeutics Acquires Dermasilk™ Brands

NEW YORK, Sept. 12, 2016 (GLOBE NEWSWIRE) -- Ember Therapeutics, Inc. (OTCQB:EMBT), a diversified New York-based pharmaceutical company developing targeted therapies for osteoarthritis, kidney fibrosis, and other regenerative medicines, today announced that it has entered into a definitive agreement for the acquisition of Dermasilk™ Brands, a commercially available over-the-counter beauty product portfolio encompassing fourteen different products. The products are currently sold at several large retailers including Rite-Aid, CVS, Wal-Mart and K-Mart.

As part of the transaction, all assets from Dermasilk Brands, Inc. will be transferred to Ember Therapeutics, Inc.

“This is our third acquisition this year. The addition of the Dermasilk™ brand of products to our product line will allow us to expand on our current relationship with major retailers and provide additional revenues to Ember. Dermasilk products have a large customer following and are developed using the highest cutting edge science,” said Joseph Hernandez, Executive Chairman of Ember Therapeutics, Inc. “The revenues generated by these products and Migralex™, our other commercially available product, will help further the development of our two Phase 3 ready clinical programs in osteoarthritis and regenerative medicine.”

Dermasilk™ products are currently available at Rite-Aid, CVS, Wal-Mart, K-Mart, local pharmacies, and online at jet.com and the product website www.dermasilkbrands.com. To learn more about Dermasilk™ please access www.dermasilkbrands.com.

About Ember Therapeutics, Inc.

Ember Therapeutics, Inc. is a diversified pharmaceutical company commercializing and developing targeted therapies for pain, osteoarthritis, kidney fibrosis and other regenerative medicines. In particular, Ember Therapeutics, Inc. has a commercial stage pain product and two late stage Phase 3 ready assets. For more information, please visit www.embertx.com.

Contact: Betty Rose (investors) (646) 406-6243 brose@embertx.com

Source:Ember Therapeutics